JANX - 2 Stocks That Have More Than Tripled This Year: Are They Buys?
2024-03-15 09:45:00 ET
Finding stocks that can triple in two years is hard enough. Finding those that can do so in a mere two months is that much more impressive. That's precisely what Viking Therapeutics (NASDAQ: VKTX) and Janux Therapeutics (NASDAQ: JANX) have accomplished since the year started -- and then some. Both companies' shares have soared by well over 200% since early January, thanks to impressive clinical progress.
No doubt existing shareholders are happy, but is it worth investing in these mid-cap biotechs after their recent runs? Let's find out.
Viking Therapeutics focuses on developing medicines for metabolic diseases. The company's portfolio includes VK2735, a potential anti-obesity therapy, and VK2809, which targets non-alcoholic steatohepatitis (NASH). Both niches are projected to grow rapidly through the end of the decade, so there are plenty of opportunities here for a mid-cap biotech. Viking Therapeutics recently completed a phase 2 study for VK2735 with flying colors, jolting its stock price .
For further details see:
2 Stocks That Have More Than Tripled This Year: Are They Buys?